Agenda

	MONDAY, JUNE 5 [™] — M	OLECULAR AND CELL	ULAR FUNCTIONS OF MECP2
--	---------------------------------	-------------------	-------------------------

10:00 am	Welcome
	SESSION 1: MECP2 BASIC AND SURPRISING FUNCTIONS
10:10 am	Keynote: Dr. Rudolf Jaenisch MECP2, Rett Syndrome, and Gene Expression
10:40 am	Dr. Yechezkel Sztainberg Antisense Oligonucleotide Therapy for the MECP2 Duplication Syndrome: A Preclinical Study
11:00 am	Dr. Michael Müller Deciphering the Mitochondrial Impairment in Rett Syndrome
11:20 am	Dr. Sameer Bajikar Timed Molecular, Behavioral, and Physiological Characterization of Mice After Adult Depletion of MeCP2 (Poster #2)
11:40 am	Dr. Jing Zhang Advancing an Understanding of MeCP2 Function by Identification of Methylated RNA Targets (Poster #52)
12:00 pm	Poster Flash Talks (#1-#26)
12:30 pm	LUNCH
1:15 pm	Dr. Ponni Subbiah, Acadia Pharmaceuticals Presenting Sponsor Presentation
	SESSION 2: CONTROL OF MECP2 (OVER)EXPRESSION
1:25 pm	Keynote: Dr. Huda Zoghbi Rett Syndrome and MECP2 Disorders: An Enlightening Dialogue Between Bench and Clinic
1:55 pm	Dr. Hume Stroud Exploring the Formation and Function of Novel MECP2 Genomic Binding Sites
2:15 pm	Dr. Vania Broccoli Improved Tools and Methods for MeCP2 Gene Replacement Therapy in Rett Syndrome
2:35 pm	Dr. James Ellis Buffering of Transcription Rate by mRNA Half-Life in Rett Syndrome Neurons and In Vitro Neurodevelopment
2:55 pm	Dr. Lisa Boxer Investigating the Immediate Consequences of Acute Loss of MeCP2 (Poster #5)
3:15 pm	BREAK
	SESSION 3: MECP2 OUTSIDE OF ITS COMFORT ZONE
3:35 pm	Keynote: Dr. Nathaniel Heintz 5hmC, MeCP2 and Epigenetic Control of Neuronal Function
4:05 pm	Dr. Nicolas Panayotis Importins: A New Target for Ameliorating Neuronal Functions in MeCP2-Related Disorders
4:25 pm	Dr. Janine LaSalle Sex Disparate Gut Microbiome and Metabolome Perturbations Precede Disease Progression in a Mouse Model of Rett Syndrome
4:45 pm	Dr. Rocco Gogliotti
FIOF mass	Insights from a Reverse Translational Approach to Rett Syndrome Target Identification
5:05 pm	Ms. Gabriella Chua Single-molecule Visualization of the Behavior of MeCP2 on Chromatin (Poster #9)
5:25 pm	Poster Flash Talks (#27-#52)
6-7:30 pm	Poster Session/Reception

Agenda

TUESDAY, JUNE 6TH - THERAPEUTIC APPROACHES FOR RETT SYNDROME

TOLSDAT, SONE O - THERAPLOTTE AFFROAGILES FOR RETT STRUKGILE		
7:00 am	BREAKFAST	
8:00 am	Welcome	
8:10 am	Panel Discussion: Day 1 Keynote Speakers	
9:10 am	Late-Breaking Poster Flash Talks (see supplemental handout)	
9:50 am	BREAK	
	SESSION 4: INSIGHTS FROM AFFECTED FAMILIES & OTHER DISORDERS	
10:00 am		
10:00 am	Keynote: Dr. Katherine High Gene Therapy for CNS Disorders: Successes, Challenges, and Opportunities	
10:30 am	Dr. Darcy Krueger Tuberous Sclerosis Complex (TSC): Is Prevention in a Rare Genetic Condition Possible?	
10:50 am	Dr. Richard Finkel	
	Developing Effective Disease-Specific Outcome Measures for a Rare Disease: The Example of Spinal Muscular Atrophy	
11:10 am	Ms. Keri Ramsey	
	Family and Caregiver Perspectives on Gene Therapy for Rett Syndrome (Poster #44)	
11:30 am	Caregiver Panel: Living with Rett Syndrome	
12:10 pm	LUNCH	
	SESSION 5: INNOVATIVE THERAPIES	
1:10 pm	Keynote: Dr. Jeannie Lee	
	Advancing X Reactivation as a Method of Treating Rett Syndrome	
1:40 pm	Dr. Ronald Emeson RNA Editing-Mediated Modification of Common Nonsense Mutations in Rett Syndrome	
2:00 pm	Dr. Yuval Tabach	
•	Expanding the MECP2 Network Using Comparative Genomics Reveals Therapeutic Options for Rett Syndrome	
2:20 pm	Dr. Julian Halmai	
	A Miniature Cas9 for Epigenetic Editing in Rett Syndrome (Poster #24)	
2:40 pm	Dr. Andrew Dietz	
	Massive Diversity Capsid Screening and Machine Learning Identify Next-Generation AAV	
	for Targeted Tissue Biodistribution (Poster #14)	
3:00 pm	BREAK	
	SESSION 6: OUTCOME MEASURES AND BIOMARKERS	
3:30 pm	Keynote: Dr. Michelle Campbell How Data Informs Drug Development	
4:00 pm	Dr. Michela Fagiolini Therapeutic Targeting of the Choroid Plexus in Rett Syndrome	
4:20 pm	Dr. Victor Faundez Rett Syndrome Biomarker Discovery Through Systems Biology	
4:40 pm	Dr. Jonathan Merritt A Predictive Model of Clinical Severity in Rett Syndrome (Poster #34)	
5-6:30 pm	Poster Session	
6:30-8 pm	Center of Excellence Director Dinner in Crescent Ballroom (By Invite Only)	

Agenda

WEDNESDAY, JUNE 7TH — TREATMENTS ON THE HORIZON FOR RETT SYNDROME

7:00 am	BREAKFAST
8:00 am	Welcome
8:05 am	Keynote: Dr. James Youakim Development of Trofinetide for Rett Syndrome: From Phase 2 Studies to Launching DAYBUE™
8:55 am	Dr. Benit Maru and Ms. Emily McGinnis Taysha's Investigational Gene Therapy Program Update
9:15 am	Dr. Stuart Cobb and Dr. Albena Patroneva NGN-401: A Novel Regulated Gene Therapy for Rett Syndrome
9:35 am	Dr. Carolyn Ellaway NTI164 A Novel, Full-Spectrum Medicinal Cannabis Derived Treatment for Rett Syndrome
9:55 am	BREAK
10:15 am	Dr. Jeff Neul Novel Study Design: Umbrella Protocol for Repurposed Drugs
10:30 am	Dr. Kathrin Meyer
	Reactivation of the Silent X Chromosome via Gene Therapy is Efficacious in Rett and Other X-linked Disorders (Poster #35)
10:45 am	Dr. Frederic Vigneault
	Discovery and Development of a Novel Broad-Acting Rett Syndrome Therapeutic Candidate (Poster #50)
11:00 am	Dr. Nicholas Tonks
	PTP1B Inhibition — A Mechanism-Based Approach to the Treatment of Rett Syndrome
11:15 am	Panel Session: Highlights & Next Steps
12:00 pm	MEETING CONCLUDES
	(Box lunch to be provided)